6929 Stock Overview
An investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 1/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
OrbusNeich Medical Group Holdings Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$4.01 |
| 52 Week High | HK$7.06 |
| 52 Week Low | HK$2.86 |
| Beta | 0 |
| 1 Month Change | -3.84% |
| 3 Month Change | 22.63% |
| 1 Year Change | -39.70% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -56.17% |
Recent News & Updates
Recent updates
OrbusNeich Medical Group Holdings (HKG:6929) Seems To Use Debt Rather Sparingly
Dec 04
Some Confidence Is Lacking In OrbusNeich Medical Group Holdings Limited (HKG:6929) As Shares Slide 28%
Jul 19OrbusNeich Medical Group Holdings Limited (HKG:6929) Shares Could Be 39% Below Their Intrinsic Value Estimate
Jul 03Is OrbusNeich Medical Group Holdings (HKG:6929) A Risky Investment?
May 28Optimistic Investors Push OrbusNeich Medical Group Holdings Limited (HKG:6929) Shares Up 27% But Growth Is Lacking
May 06OrbusNeich Medical Group Holdings' (HKG:6929) Earnings Are Weaker Than They Seem
Apr 25Some Confidence Is Lacking In OrbusNeich Medical Group Holdings Limited (HKG:6929) As Shares Slide 26%
Mar 13Returns At OrbusNeich Medical Group Holdings (HKG:6929) Appear To Be Weighed Down
Feb 04A Look At The Intrinsic Value Of OrbusNeich Medical Group Holdings Limited (HKG:6929)
Oct 20Some OrbusNeich Medical Group Holdings Limited (HKG:6929) Shareholders Look For Exit As Shares Take 28% Pounding
Jun 01Shareholder Returns
| 6929 | HK Medical Equipment | HK Market | |
|---|---|---|---|
| 7D | -4.5% | -1.6% | -0.5% |
| 1Y | -39.7% | -27.9% | 19.9% |
Return vs Industry: 6929 underperformed the Hong Kong Medical Equipment industry which returned -27.9% over the past year.
Return vs Market: 6929 underperformed the Hong Kong Market which returned 19.9% over the past year.
Price Volatility
| 6929 volatility | |
|---|---|
| 6929 Average Weekly Movement | 7.1% |
| Medical Equipment Industry Average Movement | 9.0% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in HK Market | 18.6% |
| 10% least volatile stocks in HK Market | 4.1% |
Stable Share Price: 6929 has not had significant price volatility in the past 3 months compared to the Hong Kong market.
Volatility Over Time: 6929's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 1,278 | David Chien | orbusneich.com |
OrbusNeich Medical Group Holdings Limited, an investment holding company, researches, develops, manufactures, trades in, sells, and markets medical devices/instruments used for the treatment of coronary and peripheral vascular diseases in Japan, Europe, the Middle East, Africa, the Asia Pacific, the People’s Republic of China, and the United States. The company offers semi-compliant balloons and scoring balloons for pre-dilatation and lesion preparation, stents for implantation, non-compliant balloons for post-dilatation, and specialty catheters, as well as sirolimus-eluting coronary stents, peripheral self-expandable stents, and paclitaxel-coated PTCA and PTA balloons. Its product portfolio covers various treatment processes in percutaneous coronary intervention (PCI) and percutaneous transluminal angioplasty (PTA) procedures.
OrbusNeich Medical Group Holdings Limited Fundamentals Summary
| 6929 fundamental statistics | |
|---|---|
| Market cap | HK$3.31b |
| Earnings (TTM) | HK$301.06m |
| Revenue (TTM) | HK$1.18b |
11.0x
P/E Ratio2.8x
P/S RatioIs 6929 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6929 income statement (TTM) | |
|---|---|
| Revenue | US$151.37m |
| Cost of Revenue | US$47.36m |
| Gross Profit | US$104.00m |
| Other Expenses | US$65.29m |
| Earnings | US$38.72m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.047 |
| Gross Margin | 68.71% |
| Net Profit Margin | 25.58% |
| Debt/Equity Ratio | 1.1% |
How did 6929 perform over the long term?
See historical performance and comparisonDividends
2.5%
Current Dividend Yield27%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/21 22:14 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
OrbusNeich Medical Group Holdings Limited is covered by 6 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Shun Kei Law | CCB International Securities Limited |
| Zhishun Siu | CCB International Securities Limited |
| null null | China International Capital Corporation Limited |